Applied Genetic Technologies stock slumps 50% on pricing $10M securities offering to fund clinical trials (update)

Stock Information for Applied Genetic Technologies Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Applied Genetic Technologies Corporation

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025
Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation
Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation
*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*
*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*
SHAREHOLDER ALERT: Weiss Law Reminds AGTC, OYST, VLDR, and BTRS Shareholders About Its Ongoing Investigations
Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022
SHAREHOLDER ALERT: Weiss Law Investigates Applied Genetic Technologies Corporation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.